An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation.

MLA

Rohner, Eduarde, et al. “An MRNA Assay System Demonstrates Proteasomal-Specific Degradation Contributes to Cardiomyopathic Phospholamban Null Mutation.” Molecular Medicine (Cambridge, Mass.), vol. 27, no. 1, Sept. 2021, p. 102. EBSCOhost, https://doi.org/10.1186/s10020-021-00362-8.

APA

Rohner, E., Witman, N., Sohlmer, J., De Genst, E., Louch, W. E., Sahara, M., & Chien, K. R. (2021). An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation. Molecular Medicine (Cambridge, Mass.), 27(1), 102. https://doi.org/10.1186/s10020-021-00362-8

Chicago

Rohner, Eduarde, Nevin Witman, Jesper Sohlmer, Erwin De Genst, William E Louch, Makoto Sahara, and Kenneth R Chien. 2021. “An MRNA Assay System Demonstrates Proteasomal-Specific Degradation Contributes to Cardiomyopathic Phospholamban Null Mutation.” Molecular Medicine (Cambridge, Mass.) 27 (1): 102. doi:10.1186/s10020-021-00362-8.